Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN-BIND-1: Biomarkers for Predicting Treatment Response in Depression
NCT01655706Phase 3Completed
- Sponsor
- University Health Network
- Start
- Apr 2012
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of escitalopram, aripiprazole in major depressive disorder (MDD), sponsored by University Health Network. Started Apr 2012; status: completed.
02
Drugs
escitalopramaripiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01655706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01655706.